KOREA UNITED PHARM, INC. (033270) Stock Statistics & Valuation Metrics

KOREA UNITED PHARM, INC. has a market cap or net worth of ₩254.06B. The enterprise value is ―.

KOREA UNITED PHARM, INC. has 15,910,775 shares outstanding. The number of shares has decreased by -2.65% in one year.

KOREA UNITED PHARM, INC.’s return on equity (ROE) is 0.08 and return on invested capital (ROIC) is 7.94%.

The current PE Ratio of KOREA UNITED PHARM, INC. is 6.6. KOREA UNITED PHARM, INC.’s PEG ratio is 0.39.

In the last 12 months, KOREA UNITED PHARM, INC. had revenue of 288.76B and earned 38.31B in profits. Earnings per share was 2.61K.

In the last 12 months, operating cash flow was 72.43B and capital expenditures -45.06B, giving a free cash flow of 27.37B billion.

KOREA UNITED PHARM, INC. pays an annual dividend of ―, resulting in a dividend yield of ―

KOREA UNITED PHARM, INC. upcoming earnings date is Aug 7, 2026, TBA (Confirmed).

KOREA UNITED PHARM, INC. as a current ratio of 5.63, with Debt / Equity ratio of 2.90%

In the past 12 months, KOREA UNITED PHARM, INC. has paid 11.50B in taxes.

KOREA UNITED PHARM, INC. EV to EBITDA ratio is 4.72, with an EV/FCF ratio of 10.30.

KOREA UNITED PHARM, INC. has ₩171.65B in cash and marketable securities with ₩13.32B in debt, giving a net cash position of ₩158.34B billion.

Gross margin is 57.97%, with operating margin of 16.94%, and net profit margin of 13.27%.

The average price target for KOREA UNITED PHARM, INC. is ―, which is 11.43% higher than the current price. The consensus rating is ―